Treatment of pulmonary hypertension

Patel, Rajendrakumar; Aronow, Wilbert S.; Patel, Laxeshkumar; Gandhi, Kaushang; Desai, Harit; Kaul, Dhiraj; Sahgal, Sumir P.

doi:10.12659/msm.882607

Cited by 14 publications

(7 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary hypertension (PH) is a disease of the progressive condition characterized by elevated pulmonary arterial pressures and pulmonary vascular resistance leading to right ventricular failure [ 10 ]. The pulmonary vascular injury underlying PH occurs in an idiopathic form or in association with other disease states or exposures and is probably a final common response to environmental or disease-related inciting factors coupled with genetically determined susceptibilities [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and risk factors in CKD patients with pulmonary hypertension: a retrospective study

et al. 2018

View full text Add to dashboard Cite

BackgroundPulmonary hypertension (PH) is a rare disease often associated with high mortality and is recently recognized as a common complication secondary to chronic kidney disease (CKD). Epidemiological data for this disorder across the spectrum of CKD is poorly understood.MethodsWe retrospectively analyzed 705 CKD patients with complete clinical records from July 2013 to September 2015. All the patients were estimated by echocardiography and PH was defined as pulmonary artery systolic pressure (PASP) > 35 mmHg. The prevalence of PH in CKD patients was investigated, and their association was evaluated with a logistic regression model.ResultsThe overall prevalence of PH was 47.38%, in which mild, moderate and severe PH accounted for 22.13, 15.04 and 10.21%, respectively. The prevalence of PH in CKD stage 1–5 was 14.29, 33.33, 38.89, 40.91 and 64.47%. The prevalence of total PH was 57.63% in PD patients and 58.82% in HD patients. Compared with the non-dialysis patients, the prevalence of PH was much higher in patients receiving dialysis. Body mass index (BMI), hemoglobin, triglyceride (TG), proteinuria, parathyroid hormone (PTH) and estimated glomerular filtration rate (eGFR) were independent risk factors of PH in CKD patients.ConclusionsThe prevalence of PH is increased with the deterioration of renal function, however, which has no direct relation to the severity of PH. PH occurs more frequently in dialysis patients. Higher BMI and TG, more sever anemia, proteinuria and secondary hyperparathyroidism, poor renal dysfunction predict predict the more prevalence of PH in CKD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Prostacyclin has been the mainstay of PH treatment for more than a decade. And it appeared to have cytoprotective and antiproliferative activities, which was also used for the treatment of CKD [ 10 ]. Therefore, the distribution of mild-moderate-severe PH in CKD stage 3–5 might be varied due to prostacyclin.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and risk factors in CKD patients with pulmonary hypertension: a retrospective study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The authors suggest that the attack of reactive oxygen species during the oxidative stress primarily affects the saturation level of fatty acyl chains and the phospholipid structure. 7,8 In contrast to systemic hypertension that is diagnosed on the basis of simple systemic blood pressure measurements, the diagnosis of PAH requires a combination of tests, e.g. This approach included a method of identification and quantification of several serum protein parameters from one ATR FTIR spectrum such as the content of total albumin, globulin and immunoglobulin as well as their relative contribution to the overall protein composition.…”

Section: Introductionmentioning

confidence: 99%

“…PAH is a chronic progressive disease of the pulmonary vasculature, characterized by an elevated pulmonary arterial pressure leading to right ventricular failure. 7,8 In contrast to systemic hypertension that is diagnosed on the basis of simple systemic blood pressure measurements, the diagnosis of PAH requires a combination of tests, e.g. functional assessment, exercise tolerance, laboratory tests, magnetic resonance imaging, and echocardiography to support right heart hypertrophy or failure.…”

Section: Introductionmentioning

confidence: 99%

Plasma biomarkers of pulmonary hypertension identified by Fourier transform infrared spectroscopy and principal component analysis

Staniszewska-Slezak

Fedorowicz

Kramkowski

et al. 2015

Analyst

View full text Add to dashboard Cite

The main goal of this study was to find specific plasma spectral markers associated with pulmonary arterial hypertension (PAH) induced by monocrotaline injection in rats. FTIR was used to monitor biochemical changes in plasma caused by PAH as compared with the systemic hypertension induced by partial ligation on the left artery and with the control group. Both pathologies, systemic and pulmonary hypertension, induced a unique response in the biochemical content of plasma, mainly related to the composition and secondary structure of plasma proteins. For PAH, β-pleated sheet components of plasma proteins were identified whereas the protein composition in systemic hypertension was dominated by unordered structures. In addition, a higher concentration of tyrosine-rich proteins was found in plasma in PAH than in systemic hypertension. The differences between both pathologies were identified also in terms of lipid composition/metabolism as well as in the content of RNA and glucose, suggesting that lipid peroxidation appears upon pulmonary hypertension development. In summary, this work demonstrates that FTIR spectroscopy supported by principal component analysis (PCA) has the potential to become a fast and non-destructive method for biochemical characterization of plasma that consequently could have a diagnostic significance in pulmonary hypertension.

show abstract

“…12 Here Ambrisentan acts as anEndothelin receptor antagonist and gradually improves symptoms of exertional dyspnoea.However, it is highly teratogenic and therefore contraindicated in pregnancy. 13,14 Our patient considerably improved post-partum with supportive care and this specific therapy.…”

Section: Introductionmentioning

confidence: 78%

Pregnancy with Severe Anaemia and Pulmonary Hypertension: A Presentation of Hb E –ß Thalassemia

Habib

Begum

Akhtaruzzaman

et al. 2018

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

show abstract

Treatment of pulmonary hypertension

Cited by 14 publications

References 64 publications

Epidemiology and risk factors in CKD patients with pulmonary hypertension: a retrospective study

Epidemiology and risk factors in CKD patients with pulmonary hypertension: a retrospective study

Plasma biomarkers of pulmonary hypertension identified by Fourier transform infrared spectroscopy and principal component analysis

Pregnancy with Severe Anaemia and Pulmonary Hypertension: A Presentation of Hb E –ß Thalassemia

Contact Info

Product

Resources

About